Impact Biomedical (IBO) Total Non-Current Liabilities (2022 - 2023)
Impact Biomedical (IBO) posted Total Non-Current Liabilities of $15.5 million for Q3 2023, up 12.1% on a QoQ basis from $13.8 million in Q4 2022.
Impact Biomedical (IBO) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Impact Biomedical's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $15.5 million for Q3 2023.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $15.5 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $15.5 million (changed N/A YoY) and the FY2022 annual result came in at $13.8 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $15.5 million for Q3 2023 at Impact Biomedical, up from $13.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $15.5 million in Q3 2023 and bottomed at $13.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 15.50 Mn |
| Dec 31, 2022 | 13.83 Mn |